{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:18:58Z","timestamp":1760242738546},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T00:00:00Z","timestamp":1434931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/onc.2015.193","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T10:04:34Z","timestamp":1434967474000},"page":"1373-1385","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism"],"prefix":"10.1038","volume":"35","author":[{"given":"C R","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A R","family":"Peck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Girondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A F","family":"Yanac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A J","family":"Kovatich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Hooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C D","family":"Shriver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E P","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hyslop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Rui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,22]]},"reference":[{"key":"BFonc2015193_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1020299707510","volume":"76","author":"WF Anderson","year":"2002","unstructured":"Anderson WF, Chatterjee N, Ershler WB, Brawley OW . Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27\u201336.","journal-title":"Breast Cancer Res Treat"},{"key":"BFonc2015193_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R . Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011; 62: 233\u2013247.","journal-title":"Ann Rev Med"},{"key":"BFonc2015193_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","volume":"608","author":"AM Gonzalez-Angulo","year":"2007","unstructured":"Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1\u201322.","journal-title":"Adv Exp Med Biol"},{"key":"BFonc2015193_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H . Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684\u20131691.","journal-title":"J Clin Oncol"},{"key":"BFonc2015193_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105\u2013111.","journal-title":"Nature"},{"key":"BFonc2015193_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","volume":"14","author":"MC Cheang","year":"2008","unstructured":"Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368\u20131376.","journal-title":"Clin Cancer Res"},{"key":"BFonc2015193_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/path.1559","volume":"203","author":"DM Abd El-Rehim","year":"2004","unstructured":"Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203: 661\u2013671.","journal-title":"J Pathol"},{"key":"BFonc2015193_CR8","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1073\/pnas.1106509108","volume":"109","author":"JM Haughian","year":"2012","unstructured":"Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 2012; 109: 2742\u20132747.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015193_CR9","first-page":"23","volume":"7","author":"K Joensuu","year":"2013","unstructured":"Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkila P . ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer 2013; 7: 23\u201334.","journal-title":"Breast Cancer"},{"key":"BFonc2015193_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s13058-014-0418-6","volume":"16","author":"AJ Knox","year":"2014","unstructured":"Knox AJ, Scaling AL, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA et al. Modeling Luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in Luminal disease. Breast Cancer Res 2014; 16: 418.","journal-title":"Breast Cancer Res"},{"key":"BFonc2015193_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00428-006-0334-y","volume":"450","author":"J Paredes","year":"2007","unstructured":"Paredes J, Lopes N, Milanezi F, Schmitt FC . P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 2007; 450: 73\u201380.","journal-title":"Virchows Arch"},{"key":"BFonc2015193_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2559.2007.02638.x","volume":"50","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO . Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007; 50: 434\u2013438.","journal-title":"Histopathology"},{"key":"BFonc2015193_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-010-1078-6","volume":"128","author":"P Kabos","year":"2011","unstructured":"Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A et al. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 2011; 128: 45\u201355.","journal-title":"Breast Cancer Res Treat"},{"key":"BFonc2015193_CR14","doi-asserted-by":"publisher","first-page":"9779","DOI":"10.1158\/0008-5472.CAN-05-0505","volume":"65","author":"CA Sartorius","year":"2005","unstructured":"Sartorius CA, Harvell DM, Shen T, Horwitz KB . Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res 2005; 65: 9779\u20139788.","journal-title":"Cancer Res"},{"key":"BFonc2015193_CR15","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1073\/pnas.0706216105","volume":"105","author":"KB Horwitz","year":"2008","unstructured":"Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA . Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008; 105: 5774\u20135779.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015193_CR16","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/onc.2013.172","volume":"33","author":"T Sato","year":"2014","unstructured":"Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR et al. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene 2014; 33: 2215\u20132224.","journal-title":"Oncogene"},{"key":"BFonc2015193_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1177\/1087057112452138","volume":"17","author":"BH Yoo","year":"2012","unstructured":"Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA et al. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen 2012; 17: 1211\u20131220.","journal-title":"J Biomol Screen"},{"key":"BFonc2015193_CR18","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/onc.2012.275","volume":"32","author":"DM Cittelly","year":"2013","unstructured":"Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P et al. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene 2013; 32: 2555\u20132564.","journal-title":"Oncogene"},{"key":"BFonc2015193_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12672-012-0127-5","volume":"4","author":"SD Axlund","year":"2013","unstructured":"Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV et al. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer 2013; 4: 36\u201349.","journal-title":"Horm Cancer"},{"key":"BFonc2015193_CR20","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1210\/mend.13.12.0396","volume":"13","author":"CC Nelson","year":"1999","unstructured":"Nelson CC, Hendy SC, Shukin RJ, Cheng H, Bruchovsky N, Koop BF et al. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Mol Endocrinol 1999; 13: 2090\u20132107.","journal-title":"Mol Endocrinol"},{"key":"BFonc2015193_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1210\/mend.16.6.0848","volume":"16","author":"Y Wan","year":"2002","unstructured":"Wan Y, Nordeen SK . Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol Endocrinol 2002; 16: 1204\u20131214.","journal-title":"Mol Endocrinol"},{"key":"BFonc2015193_CR22","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1128\/MCB.23.11.3763-3773.2003","volume":"23","author":"X Li","year":"2003","unstructured":"Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW . Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 2003; 23: 3763\u20133773.","journal-title":"Mol Cell Biol"},{"key":"BFonc2015193_CR23","doi-asserted-by":"publisher","first-page":"e29021","DOI":"10.1371\/journal.pone.0029021","volume":"7","author":"P Yin","year":"2012","unstructured":"Yin P, Roqueiro D, Huang L, Owen JK, Xie A, Navarro A et al. Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells. PLoS one 2012; 7: e29021.","journal-title":"PLoS one"},{"key":"BFonc2015193_CR24","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1158\/0008-5472.CAN-09-2314","volume":"70","author":"TH Tran","year":"2010","unstructured":"Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A et al. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 2010; 70: 1711\u20131721.","journal-title":"Cancer Res"},{"key":"BFonc2015193_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/sj.onc.1209775","volume":"26","author":"SR Walker","year":"2007","unstructured":"Walker SR, Nelson EA, Frank DA . STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 2007; 26: 224\u2013233.","journal-title":"Oncogene"},{"key":"BFonc2015193_CR26","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1210\/me.2007-0173","volume":"21","author":"LM Neilson","year":"2007","unstructured":"Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU et al. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a\/b pathways. Mol Endocrinol 2007; 21: 2218\u20132232.","journal-title":"Mol Endocrinol"},{"key":"BFonc2015193_CR27","first-page":"3763","volume":"9","author":"T Ouatas","year":"2003","unstructured":"Ouatas T, Halverson D, Steeg PS . Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res 2003; 9: 3763\u20133772.","journal-title":"Clin Cancer Res"},{"key":"BFonc2015193_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0303-7207(99)00109-4","volume":"154","author":"JM Bentel","year":"1999","unstructured":"Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD . Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 1999; 154: 11\u201320.","journal-title":"Mol Cell Endocrinol"},{"key":"BFonc2015193_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2006.07.1522","volume":"25","author":"S Loi","year":"2007","unstructured":"Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239\u20131246.","journal-title":"J Clin Oncol"},{"key":"BFonc2015193_CR30","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/0008-5472.CAN-03-2546","volume":"64","author":"W Wu","year":"2004","unstructured":"Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD . Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64: 1757\u20131764.","journal-title":"Cancer Res"},{"key":"BFonc2015193_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4161\/cbt.5.8.2875","volume":"5","author":"D Pang","year":"2006","unstructured":"Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD . Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 2006; 5: 933\u2013940.","journal-title":"Cancer Biol Ther"},{"key":"BFonc2015193_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4161\/cbt.6.2.3652","volume":"6","author":"C Zhang","year":"2007","unstructured":"Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P et al. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 2007; 6: 278\u2013287.","journal-title":"Cancer Biol Ther"},{"key":"BFonc2015193_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jpsychores.2007.05.012","volume":"63","author":"O Palesh","year":"2007","unstructured":"Palesh O, Butler LD, Koopman C, Giese-Davis J, Carlson R, Spiegel D . Stress history and breast cancer recurrence. J Psychosom Res 2007; 63: 233\u2013239.","journal-title":"J Psychosom Res"},{"key":"BFonc2015193_CR34","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.bbi.2012.10.022","volume":"30","author":"PA Volden","year":"2013","unstructured":"Volden PA, Conzen SD . The influence of glucocorticoid signaling on tumor progression. Brain Behav Immun 2013; 30: S26\u2013S31.","journal-title":"Brain Behav Immun"},{"key":"BFonc2015193_CR35","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/ncponc1134","volume":"5","author":"Y Chida","year":"2008","unstructured":"Chida Y, Hamer M, Wardle J, Steptoe A . Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 2008; 5: 466\u2013475.","journal-title":"Nat Clin Pract Oncol"},{"key":"BFonc2015193_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.iac.2010.09.001","volume":"31","author":"ES Costanzo","year":"2011","unstructured":"Costanzo ES, Sood AK, Lutgendorf SK . Biobehavioral influences on cancer progression. Immunol Allergy Clin North Am 2011; 31: 109\u2013132.","journal-title":"Immunol Allergy Clin North Am"},{"key":"BFonc2015193_CR37","first-page":"77","volume":"23","author":"I Conde","year":"2008","unstructured":"Conde I, Paniagua R, Fraile B, Lucio J, Arenas MI . Glucocorticoid receptor changes its cellular location with breast cancer development. Histol Histopathol 2008; 23: 77\u201385.","journal-title":"Histol Histopathol"},{"key":"BFonc2015193_CR38","first-page":"2001","volume":"17","author":"H Sasano","year":"1997","unstructured":"Sasano H, Frost AR, Saitoh R, Matsunaga G, Nagura H, Krozowski ZS et al. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders. Anticancer Res 1997; 17: 2001\u20132007.","journal-title":"Anticancer Res"},{"key":"BFonc2015193_CR39","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.1997.15.9.3141","volume":"15","author":"MJ Byrne","year":"1997","unstructured":"Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. J Clin Oncol 1997; 15: 3141\u20133148.","journal-title":"J Clin Oncol"},{"key":"BFonc2015193_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)00020-0","volume":"13","author":"AL Shaffer","year":"2000","unstructured":"Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM . BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13: 199\u2013212.","journal-title":"Immunity"},{"key":"BFonc2015193_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08420.x","volume":"152","author":"SD Wagner","year":"2011","unstructured":"Wagner SD, Ahearne M, Ferrigno PK . The role of BCL6 in lymphomas and routes to therapy. Br J Haematol 2011; 152: 3\u201312.","journal-title":"Br J Haematol"},{"key":"BFonc2015193_CR42","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature09883","volume":"473","author":"C Duy","year":"2011","unstructured":"Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011; 473: 384\u2013388.","journal-title":"Nature"},{"key":"BFonc2015193_CR43","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1038\/sj.onc.1206689","volume":"22","author":"S Logarajah","year":"2003","unstructured":"Logarajah S, Hunter P, Kraman M, Steele D, Lakhani S, Bobrow L et al. BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene 2003; 22: 5572\u20135578.","journal-title":"Oncogene"},{"key":"BFonc2015193_CR44","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1471-2407-14-418","volume":"14","author":"Q Wu","year":"2014","unstructured":"Wu Q, Liu X, Yan H, He YH, Ye S, Cheng XW et al. B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells. BMC Cancer 2014; 14: 418.","journal-title":"BMC Cancer"},{"key":"BFonc2015193_CR45","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1200\/JCO.2010.30.3552","volume":"29","author":"AR Peck","year":"2011","unstructured":"Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011; 29: 2448\u20132458.","journal-title":"J Clin Oncol"},{"key":"BFonc2015193_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1677\/erc.1.01095","volume":"13","author":"H Yamashita","year":"2006","unstructured":"Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K et al. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2006; 13: 885\u2013893.","journal-title":"Endocr Relat Cancer"},{"key":"BFonc2015193_CR47","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/sj.onc.1208203","volume":"24","author":"AS Sultan","year":"2005","unstructured":"Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H . Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005; 24: 746\u2013760.","journal-title":"Oncogene"},{"key":"BFonc2015193_CR48","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/0008-5472.CAN-05-2292","volume":"66","author":"Z Nouhi","year":"2006","unstructured":"Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S . Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006; 66: 1824\u20131832.","journal-title":"Cancer Res"},{"key":"BFonc2015193_CR49","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.2004.11.046","volume":"22","author":"MT Nevalainen","year":"2004","unstructured":"Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004; 22: 2053\u20132060.","journal-title":"J Clin Oncol"},{"key":"BFonc2015193_CR50","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/bcr3328","volume":"14","author":"AR Peck","year":"2012","unstructured":"Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res 2012; 14: R130.","journal-title":"Breast Cancer Res"},{"key":"BFonc2015193_CR51","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1158\/0008-5472.CAN-08-4033","volume":"69","author":"A Plotnikov","year":"2009","unstructured":"Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY . Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Res 2009; 69: 3165\u20133172.","journal-title":"Cancer Res"},{"key":"BFonc2015193_CR52","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/bcr3467","volume":"15","author":"N Yang","year":"2013","unstructured":"Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH et al. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Res 2013; 15: R73.","journal-title":"Breast Cancer Res"},{"key":"BFonc2015193_CR53","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.2353\/ajpath.2010.090399","volume":"177","author":"KJ Johnson","year":"2010","unstructured":"Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB et al. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol 2010; 177: 2971\u20132983.","journal-title":"Am J Pathol"},{"key":"BFonc2015193_CR54","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1349-7006.2007.00685.x","volume":"99","author":"AS Sultan","year":"2008","unstructured":"Sultan AS, Brim H, Sherif ZA . Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci 2008; 99: 272\u2013279.","journal-title":"Cancer Sci"},{"key":"BFonc2015193_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1476-4598-12-59","volume":"12","author":"T Sato","year":"2013","unstructured":"Sato T, Tran TH, Peck AR, Liu C, Ertel A, Lin J et al. Global profiling of prolactin-modulated transcripts in breast cancer in vivo. Mol Cancer 2013; 12: 59.","journal-title":"Mol Cancer"},{"key":"BFonc2015193_CR56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1198\/106186006X133933","volume":"15","author":"T Hothorn","year":"2006","unstructured":"Hothorn T, Hornik K, Zeileis A . Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 2006; 15: 651\u2013674.","journal-title":"J Comput Graph Stat"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2015193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015193","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:58:20Z","timestamp":1684472300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2015193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,22]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFonc2015193"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.193","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,22]]},"assertion":[{"value":"23 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}